HK8092A - Fused tricyclic derivatives of naphthyridinone and pyridone and the corresponding thiones - Google Patents

Fused tricyclic derivatives of naphthyridinone and pyridone and the corresponding thiones

Info

Publication number
HK8092A
HK8092A HK80/92A HK8092A HK8092A HK 8092 A HK8092 A HK 8092A HK 80/92 A HK80/92 A HK 80/92A HK 8092 A HK8092 A HK 8092A HK 8092 A HK8092 A HK 8092A
Authority
HK
Hong Kong
Prior art keywords
naphthyridinone
pyridone
fused tricyclic
tricyclic derivatives
corresponding thiones
Prior art date
Application number
HK80/92A
Other languages
English (en)
Inventor
David John Glythin
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HK8092A publication Critical patent/HK8092A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HK80/92A 1983-05-31 1992-01-23 Fused tricyclic derivatives of naphthyridinone and pyridone and the corresponding thiones HK8092A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49958483A 1983-05-31 1983-05-31
US06/597,887 US4680298A (en) 1983-05-31 1984-04-09 Tricyclic anti-allergy and use as anti-inflammatory agents

Publications (1)

Publication Number Publication Date
HK8092A true HK8092A (en) 1992-01-31

Family

ID=27053194

Family Applications (1)

Application Number Title Priority Date Filing Date
HK80/92A HK8092A (en) 1983-05-31 1992-01-23 Fused tricyclic derivatives of naphthyridinone and pyridone and the corresponding thiones

Country Status (14)

Country Link
US (1) US4680298A (fr)
EP (1) EP0127135B1 (fr)
JP (1) JPH0747590B2 (fr)
AU (1) AU559754B2 (fr)
CA (1) CA1251208A (fr)
DE (1) DE3483064D1 (fr)
DK (1) DK160557C (fr)
GB (1) GB2142013B (fr)
GR (1) GR81552B (fr)
HK (1) HK8092A (fr)
IL (1) IL71960A (fr)
NZ (1) NZ208310A (fr)
PH (1) PH22970A (fr)
SG (1) SG83890G (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK127086A (da) * 1985-03-25 1986-09-26 Schering Corp Substituerede 1,8-naphthyridoner, fremgangsmaader til deres fremstilling og farmaceutiske kompositioner, der indeholder disse forbindelser
US4596809A (en) * 1985-03-25 1986-06-24 Schering Corporation Substituted 1,8-naphthyridinones, useful as anti-allergic agents
NZ216519A (en) 1985-06-13 1989-02-24 Schering Corp Polycyclic compounds and pharmaceutical compositions
US4810708A (en) * 1986-05-15 1989-03-07 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
US4988705A (en) * 1985-06-13 1991-01-29 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
US5116840A (en) * 1985-06-13 1992-05-26 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
WO1986007537A2 (fr) * 1985-06-18 1986-12-31 Schering Corporation Compositions pharmaceutiques contenant des azanaphtalenes
US4801589A (en) * 1986-06-12 1989-01-31 Schering Corporation Method for suppressing the immune response
US5011860A (en) * 1986-04-11 1991-04-30 Schering Corporation Aryl-substituted naphthyridine and pyridopyrazine derivatives and their use in treating hyperproliferative skin diseases
US4760073A (en) * 1986-04-11 1988-07-26 Schering Corporation Aryl-substituted naphthyridine and pyridopyrazine derivatives, useful as anti-allergic agents
ES2054665T3 (es) * 1986-04-11 1994-08-16 Schering Corp Derivados de naftiridina y piridopirazina sustituidos con arilo.
US4882332A (en) * 1986-10-20 1989-11-21 Schering Corporation Immune suppression method employing arly-substituted naphthyridine and pyridopyrazine derivatives
US5037826A (en) * 1986-10-15 1991-08-06 Schering Corporation 1-substituted naphthyridine and pyridopyrazine derivatives
US5045542A (en) * 1986-10-20 1991-09-03 Schering Corporation Immune suppression method employing aryl-substituted naphthyridine and pyridopyrazine derivatives
CA1309658C (fr) * 1986-12-05 1992-11-03 David J. Blythin Compositions pharmaceutiques pour le traitement des maladies hyperproliferatives de la peau
US4740511A (en) * 1987-02-18 1988-04-26 Schering Corporation Method of treating hyperproliferative skin disease
US5350755A (en) * 1986-12-05 1994-09-27 Schering Corporation Compounds and methods for treating hyperproliferative skin disease
DE3780649T2 (de) * 1987-07-15 1992-12-10 Schering Corp Kondensierte benzazepine.
US4897487A (en) * 1988-04-06 1990-01-30 Schering Corporation Process for preparing intermediates for pharmaceutically useful bicyclic compounds
WO1989002739A1 (fr) * 1987-10-05 1989-04-06 Pfizer Inc. Derives de 4-aminopyridine
US5202440A (en) * 1987-10-05 1993-04-13 Pfizer Inc. Certain 9-amino-2-(or 4)-oxa 1,2,3,4-tetrahydro- or 1,2,3,4,5,6,7,8-octahydro-acridines
US4859669A (en) * 1987-12-23 1989-08-22 Schering Corporation Antiinflammatory and anti-hyperproliferative naphthyridin-4-ones
US5180823A (en) * 1988-04-06 1993-01-19 Schering Corporation Processes for preparing bicyclic compounds
US5079360A (en) * 1988-04-06 1992-01-07 Schering Corporation Processes for preparing bicyclic compounds and intermediates thereof
US4996212A (en) * 1989-12-21 1991-02-26 Schering Corporation Antiinflammatory and anti-hyperproliferative compounds
US7138393B2 (en) 1998-07-24 2006-11-21 Wyeth Biologically active vasopressin agonist metabolites
ATE445838T1 (de) 2001-07-25 2009-10-15 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
DK1889198T3 (da) 2005-04-28 2015-02-09 Proteus Digital Health Inc Farma-informatiksystem
WO2008036682A2 (fr) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Traitement des troubles hépatiques par l'administration de conjugués de protéine associée au récepteur (rap)
EP2367821B1 (fr) * 2008-12-17 2015-09-16 Merck Patent GmbH Inhibiteurs de protéines kinases de type benzonaphtyridinones tricycliques modifiées sur le noyau c et leur utilisation
ES2728225T3 (es) 2009-02-20 2019-10-23 2 Bbb Medicines B V Sistema de administración de fármacos a base de glutatión
US8445002B2 (en) 2009-05-06 2013-05-21 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
CN113943288A (zh) * 2020-07-17 2022-01-18 微境生物医药科技(上海)有限公司 5,6-二氢吡嗪并[2,3-c]异喹啉化合物
CN115611896A (zh) * 2021-07-16 2023-01-17 中国药科大学 含四氢萘啶酮或四氢吡啶并嘧啶酮骨架的化合物及其制备方法与制药用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB855022A (en) * 1957-08-06 1960-11-30 Geigy Ag J R Improvements in and relating to carbostyril derivatives
IT1054655B (it) * 1975-08-27 1981-11-30 Lepetit Spa Derivati condensati del l isochinolina
JPS5854152B2 (ja) * 1976-03-25 1983-12-02 久光製薬株式会社 新規なナフチリジン誘導体
DE2963332D1 (en) * 1978-05-26 1982-09-02 Lepetit Spa Pyrazolo (3,4-c) and thiazolo (5,4-c) isoquinolines, methods for preparing them, these compounds for use as antiinflammatory, cns-depressant and anti-anxiety agents and pharmaceutical compositions thereof
NL89090C (fr) * 1978-06-05
US4452800A (en) * 1982-04-26 1984-06-05 Schering Corporation Salts of 3(n-butyl)-4-hydroxy-1-phenyl-1,8-naphthyridine-2(1H)-one and their use in treating chronic obstructive lung diseases
EP0092786B1 (fr) * 1982-04-26 1987-01-07 Schering Corporation Dérivés de la 1,8-naphtyridine et de la 1,5,8-azanaphtyridine

Also Published As

Publication number Publication date
GB2142013A (en) 1985-01-09
GB8413582D0 (en) 1984-07-04
DK264784A (da) 1984-12-01
IL71960A (en) 1988-07-31
JPS6034967A (ja) 1985-02-22
DK160557B (da) 1991-03-25
CA1251208A (fr) 1989-03-14
GB2142013B (en) 1987-01-21
EP0127135A3 (en) 1985-08-21
EP0127135B1 (fr) 1990-08-29
JPH0747590B2 (ja) 1995-05-24
EP0127135A2 (fr) 1984-12-05
DK264784D0 (da) 1984-05-29
AU2882484A (en) 1984-12-06
AU559754B2 (en) 1987-03-19
GR81552B (fr) 1984-12-11
DE3483064D1 (de) 1990-10-04
DK160557C (da) 1991-09-09
US4680298A (en) 1987-07-14
SG83890G (en) 1990-11-23
PH22970A (en) 1989-02-10
NZ208310A (en) 1986-11-12
IL71960A0 (en) 1984-09-30

Similar Documents

Publication Publication Date Title
HK8092A (en) Fused tricyclic derivatives of naphthyridinone and pyridone and the corresponding thiones
IL73190A0 (en) Cephalosporin derivatives and processes for their preparation
NZ210135A (en) 2-pyridylmethyl-thio and sulphinyl-benzimidazole derivatives
AU551596B2 (en) Naphthyridine and dinhydro quinoline derivatives
AR242579A1 (es) Procedimiento para la preparacion de derivados de piridon carboxamida.
ZA826538B (en) Thieno and furopyridinium-substituted cephalosporin derivatives
AR242017A1 (es) Procedimiento para la preparacion de derivados de pent-4-en-1-ino.
DE3274106D1 (en) Alpha-phenyl-2-(aza)benzothiazolylthioglycolic acids and derivatives thereof
GB2146329B (en) Naphthalenylimidazopyridine and derivatives and their preparation
GR80197B (en) Method for the preparation of benzodiazepin derivatives
GB2144421B (en) Indolizines and quinolizines
PH21682A (en) Dihydroindenothiadiazinone and dihydronaphthothiadiazinone derivatives
GB2149404B (en) Imidazopyridines and purines
ZA849903B (en) Derivatives of pyrazolopyridine
ZA844083B (en) Fused tricyclic derivatives of naphthyridione,pyridone and quinolone and the corresponding thiones
GB2133013B (en) New cephalosporins and processes for their preparation
GB2138803B (en) 2-guanidino-4-hydroxymethylthiazole and derivatives thereof
ZA823878B (en) A-phenyl-2-(aza)benzothiazolythioglycolic acids and derivatives thereof
GB8431989D0 (en) Pyrazolopyridine derivatives
IL69080A0 (en) Keto-aldehyde derivatives and their preparation
GB8412638D0 (en) Cephalosporanic and penicillanic derivatives
DE3475710D1 (en) Cephalosporin derivatives and process for their preparation
ZA841711B (en) Anti-inflammatory pyrazolo pyridines
JPS56127374A (en) Pyrazolopyridines and manufacture
IL84058A0 (en) Bicyclic heterocyclic compounds and their preparation